[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autonomous-cortisol-secretion-acs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autonomous-cortisol-secretion-acs":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100603573","phase-2-metyrapone-study-for-patients-diagnosed-with-mild-autonomous-cortisol-secretion---macs-100603573",false,"NCT07138274","Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS","A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Metyrapone in Subjects Diagnosed With Mild Autonomous Cortisol Secretion (MACS)","Inclusion Criteria:\n\n1. Provide written informed consent.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Age ≥ 18 years\n4. Diagnosed with MACS i. at least 2 abnormal post-dexamethasone cortisol results1 mg post-dexamethasone cortisol \\>1.8 mcg\u002FdL or ii. 8 mg post-dexamethasone cortisol \\>1 mcg\u002FdL b. Historical dexamethasone suppression test results can be used if performed within 24 months prior to enrollment.\n5. Adrenal imaging phenotype consistent with benign disease (adrenal adenoma\u002Fs, macronodular or micronodular adrenal hyperplasia)\n6. At least one of the following comorbidities:\n\n   1. obesity (BMI\\>30 kg\u002Fm2)\n   2. dysglycemia\n   3. dyslipidemia\n   4. hypertension\n   5. osteopenia\n   6. osteoporosis\n   7. fragility fractures\n7. Ability to take oral medication and be willing to adhere to the study intervention regimen.\n8. For persons of childbearing potential: : agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of ≤ 5% per year during the treatment period and for 1 month after the last dose of study treatment.\n9. Stable timing for bedtime for at least one week prior to on-site study visits.\n10. History of difficulty providing blood via standard blood draw methods\n\nExclusion Criteria:\n\n1. Planned alternative therapy for MACS within 12 months after joining the study.\n2. Current use of oral exogenous glucocorticoid therapy\n3. Current use of opioid therapy \\>20 MME\u002Fday\n4. Planned use of oral exogenous glucocorticoid therapy\n5. Planned use of opioid therapy \\>20 MME\u002Fday\n6. Use of injectable glucocorticoid within 6 weeks prior to Day 1\n7. Investigator's judgement based on history\u002Fphysical examination that a comorbidity or concomitant medication may impact the hypothalamic-pituitary-adrenal axis or steroid metabolome\n8. Uncontrolled intercurrent illness including, but not limited to:\n\n   * Ongoing or active infection\n   * Symptomatic congestive heart failure\n   * Unstable angina pectoris\n   * Cardiac arrhythmia\n   * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n9. Pregnancy or lactation\n10. Known allergic reactions to metyrapone\n11. Suspected false positive post-dexamethasone cortisol results due to increased metabolism, poor absorption, or noncompliance with dexamethasone\n12. Treatment with another investigational drug or other intervention within lower than specific therapy washout period","ALL","18 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.",[26,27],"Mild Autonomous Cortisol Secretion (MACS)","Autonomous Cortisol Secretion (ACS)",[29,30,31,32,33],"Hypercortisolism","Cortisol excess","Cushing Syndrome","Adrenal adenoma","Adrenal hyperplasia","NOT_YET_RECRUITING","2026-06-25",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":20},"2026-08",{"date":42,"type":20},"2031-12",{"name":44,"class":45},"Mayo Clinic","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100620765","impact-macs-adrenalectomy-vs-semaglutide-for-metabolic-outcomes-in-mild-autonomous-cortisol-secretion-100620765","NCT07361874","IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion","IMPACT-MACS Study: Investigating the Mechanisms, Pathophysiology, and Cardiometabolic Treatment in Mild Autonomous Cortisol Secretion","IMPACT-MACS","Inclusion Criteria:\n\n* Adults ≥18 years\n* MACS groups: adrenal adenoma + DST cortisol \\>1.8 µg\u002FdL + no overt Cushing + eligible for adrenalectomy\n* Willingness to postpone surgery 6 months if randomized\n* Controls: no adrenal abnormalities + normal DST + BMI ≥27 + ≥2 cardiometabolic conditions\n* Stable medication doses for ≥4 weeks\n* Negative pregnancy test if applicable\n\nExclusion Criteria:\n\n* Prior GLP-1 RA within 90 days\n* Weight change \\>5 kg in past 90 days\n* Prior obesity\u002Fdiabetes surgery\n* Type 1 diabetes or other diabetes types\n* Severe organ disease\n* Recent pancreatitis\n* Pregnancy, breastfeeding\n* Contraindication to semaglutide\n* Contraindication to surgery delay\n* Chronic glucocorticoid use",{"count":55,"type":20},75,[57],"NA","The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with mild autonomous cortisol secretion (MACS). The study will also learn how these treatments impact body composition, blood pressure, cholesterol, inflammation, muscle strength, and quality of life.\n\nThe main questions the study aims to answer are:\n\n1. Does adrenalectomy or semaglutide improve insulin resistance more in people with MACS?\n2. How do these treatments change cortisol patterns and other cardiometabolic risk factors?\n3. Do people with MACS respond differently to semaglutide compared to matched adults without MACS?\n\nParticipants will:\n\n1. Receive either adrenalectomy or semaglutide if they have MACS, or semaglutide if they are matched controls\n2. Complete clinic visits and phone visits over about 26-30 weeks\n3. Undergo metabolic testing such as blood tests, urine steroid profiling, body composition scans, blood pressure monitoring, muscle strength testing, and questionnaires about health and well-being",[26,27,60,61],"Subclinical Cushing's","Mild Autonomous Cortisol Excess",[63,64,65,32,66,29,67,68,69,70,71,72,73,74,75,76,77,78],"Mild Autonomous Cortisol Secretion","MACS","Adrenal incidentaloma","Subclinical Cushing","Cortisol dysregulation","Adrenalectomy","Semaglutide","Weight loss","Body composition","Insulin resistance","GLP-1 receptor agonist","Hyperinsulinemic-euglycemic clamp","Cortisol dynamics","Visceral fat","cardiometabolic risk","randomized controlled trial","RECRUITING","2026-03-25",{"date":82,"type":38},"2026-03-27",{"date":84,"type":38},"2026-03-05",{"date":86,"type":20},"2030-05-31",{"name":88,"class":45},"University of Texas Southwestern Medical Center",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":89},"100601001","phase-2-impact-of-1-mg-osilodrostat-therapy-on-mild-autonomous-cortisol-secretion-macs-100601001","NCT07104812","Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)","Inclusion Criteria:\n\n* Provide written informed consent\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Age ≥ 18 years\n* Diagnosed with MACS\n\n  * At least 2 abnormal post-dexamethasone cortisol results:\n\n    i. 1 mg post-dexamethasone cortisol \\>1.8 mcg\u002FdL or ii. 8 mg post-dexamethasone cortisol \\>1 mcg\u002FdL\n  * Historical dexamethasone suppression test results can be used if performed within 24 months prior to enrollment.\n* Adrenal imaging phenotype consistent with benign disease (adrenal adenoma\u002Fs, macronodular or micronodular adrenal hyperplasia)\n* At least one of the following comorbidities:\n\n  * Obesity (BMI\\>30 kg\u002Fm2)\n  * Dysglycemia\n  * Dyslipidemia\n  * Hypertension\n  * Osteopenia\n  * Osteoporosis\n  * Fragility fractures\n* Ability to take oral medication and be willing to adhere to the study intervention regimen\n* For persons of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of ≤ 5% per year during the treatment period and for 1 month after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Planned alternative therapy for MACS during the study period\n* Current use of oral exogenous glucocorticoid therapy\n* Current use of opioid therapy \\>20 MME\u002Fday\n* Planned use of oral exogenous glucocorticoid therapy\n* Planned use of opioid therapy \\>20 MME\u002Fday\n* Use of injectable glucocorticoid within the last 6 weeks or anticipated glucocorticoid use during the study period.\n* Hypokalemia of hypomagnesemia at baseline visit\n* Prolonged QTc on baseline ECG\n* Concomitant therapy with medications likely to lead to drug-drug interactions (based on PI review).\n* Investigator's judgement based on history\u002Fphysical examination that a comorbidity or concomitant medication may impact the hypothalamic-pituitary-adrenal axis or steroid metabolome\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnancy or lactation\n* Known allergic reactions to osilodrostat\n* Suspected false positive post-dexamethasone cortisol results due to increased metabolism, poor absorption, or noncompliance with dexamethasone.\n* Treatment with another investigational drug or other intervention within lower than specific therapy washout period",{"count":97,"type":20},15,[23],"The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol\u002Fcortisone concentrations",[63,27],[102,103,32,33,31],"hypercortisolism","cortisol excess","2026-02-08",{"date":106,"type":38},"2026-02-11",{"date":108,"type":38},"2026-01-14",{"date":110,"type":20},"2027-01",{"name":44,"class":45}]